Avadel Pharmaceuticals PLC Sponsored ADR Stock

$8.39

2.57% today

Nasdaq, Feb 05, 04:17 pm CET

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Avadel Pharmaceuticals PLC Sponsored ADR Stock price

$8.18

+1.08 15.21% 5Y

Nasdaq, Closing price Tue, Feb 04 2025

+0.21 2.63%

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$788.24m
Enterprise Value	$758.81m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	5.49
P/S ratio (TTM) P/S ratio	5.71
P/B ratio (TTM) P/B ratio	10.55
Revenue growth (TTM) Revenue growth	1,523.50%
Revenue (TTM) Revenue	$138.16m
EBIT (operating result TTM) EBIT	$-64.00m
Free Cash Flow (TTM) Free Cash Flow	$-81.98m
Cash position	$65.81m
EPS (TTM) EPS	$-0.77
P/E forward	negative
P/S forward	4.67
EV/Sales forward	4.50
Short interest	12.10%

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Get Started for Free Today

Avadel Pharmaceuticals PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Avadel Pharmaceuticals PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	138 138	1,524% 1,524% 100%
- Direct Costs	11 11	343% 343% 8%
Gross Profit	129 129	2,054% 2,054% 93%
- Selling and Administrative Expenses	178 178	45% 45% 129%
- Research and Development Expense	13 13	23% 23% 10%
EBITDA	-62 -62	54% 54% -45%
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-64 -64	53% 53% -46%
Net Profit	-73 -73	54% 54% -53%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Avadel Pharmaceuticals PLC Sponsored ADR Stock News

Positive

MarketBeat

●

16 days ago

There May Still Be Time to Get in on These 3 Trending Biotechs

Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.

Positive

Seeking Alpha

●

23 days ago

3 Oversold Biotech Names

High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.

Negative

Seeking Alpha

●

24 days ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challenges and to increase uptake among patients switching from other oxybates. Last year's legal updates have significantly reduced the risk of ruin, with Lumryz staying on the market for narcolepsy, but ...

More Avadel Pharmaceuticals PLC Sponsored ADR News

Company Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Gregory Divis
Employees	154
Founded	2015
Website	www.avadel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now